Brief: Moonlake Immunotherapeutics Announces Positive Regulatory Feedback From Both FDA And EMA On Path For The Phase 3 Program For The Nanobody® Sonelokimab In Psoriatic Arthritis
10/06/2024 13:09
June 10 (Reuters) - MoonLake Immunotherapeutics
MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE REGULATORY
FEEDBACK FROM BOTH FDA AND EMA ON PATH FOR THE PHASE 3 PROGRAM
FOR THE NANOBODY® SONELOKIMAB IN PSORIATIC ARTHRITIS
* MOONLAKE IMMUNOTHERAPEUTICS: FIRST PATIENT EXPECTED TO BE
RANDOMIZED IN Q4 2024; PRIMARY ENDPOINT READOUT EXPECTED
END-2026
Source text for Eikon: ID:nGNX7XKsYs
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial